Top Wall Street analysts changed outlook on top names. See all rating changes on analyst ratings page. Analysts have positive views on FTH stock.
Top Wall Street analysts changed their outlook on these top names.
For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Oppenheimer analyst Jay Olson initiated coverage on Faeth Therapeutics, Inc (NASDAQ:FTH) with an Outperform rating and announced a price target of $60.
Faeth Therapeutics shares closed at $29.24 on Monday.
See how other analysts view this stock.
Top Wall Street analysts changed outlook on top names. See all changes, including upgrades/downgrades, on our analyst ratings…
Top Wall Street analysts change outlook on top names. See analyst ratings page for changes, including…
Top Wall Street analysts changed their outlook on top names. See upgrades, downgrades & initiations on analyst ratings page.…
Wall Street analysts changed outlook on top stocks. To see all changes, visit the analyst ratings page. FAST stock has a Buy…
Wall Street analysts initiated coverage on various top stocks, including VCYT, UMAC, FISN, LTRX, and TNGX with positive ratings…
Wall Street analysts change outlook on top stocks. For detailed ratings, upgrades/downgrades, see analyst ratings page. Consider…
